Indian Bulk Drug Makers Trim Production In Face Of Rising Costs
This article was originally published in PharmAsia News
Indian makers of bulk drugs are trimming production of several popular drugs in the face of high prices of the raw materials they use. Some producers of active pharmaceutical ingredients for antibiotics, paracetamon and anti-diarrhea drugs have cut their output as much as by half. The makers blame a short supply and a sharp increase in materials imported from China, a consequence, in part, of crude oil prices and an environmental crackdown in advance of the summer Olympics. (Click here for more
You may also be interested in...
Guardant’s CEO anticipates accelerated adoption and reimbursement of its FDA-approved liquid biopsy assay and more biopharma partnerships.
Public Company Edition: The German mRNA-focused company could raise up to $245m based on its proposed price range, but investor interest could drive the offering’s total higher. Also, Perceptive launches another SPAC, Regeneron sells $2bn in debt and Biohaven secures up to $950m.
Agency commissioner appeals to AMA audience to communicate message that FDA review decisions are based on good science.